Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekt- og sikkerhedsundersøgelse af Frexalimab (SAR441344) hos voksne med ikke-tilbagefaldende sekundær progressiv multipel sklerose (FREVIVA)

4. november 2026 opdateret af: Sanofi

Et randomiseret, dobbeltblindt fase 3-studie, der sammenligner effektivitet og sikkerhed af Frexalimab (SAR441344) med placebo hos voksne deltagere med ikke-tilbagefaldende sekundær progressiv multipel sklerose

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include:

  • This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first participant to the common study end.
  • The number of scheduled visits will be up to 25 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
  • If the prespecified number of events for 6-month cCDP is not reached by V21/W180, scheduled visits will continue every 3 months.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

943

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320001
      • Buenos Aires, Argentina, 1012
        • Investigational Site Number : 0320002
      • Buenos Aires, Argentina, 1055
        • Investigational Site Number : 0321010
      • Buenos Aires, Argentina, 1060
        • Investigational Site Number : 0320007
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320003
    • New South Wales
      • Saint Leonards, New South Wales, Australien, 2065
        • Investigational Site Number : 0360005
    • Queensland
      • Woolloongabba, Queensland, Australien, 4102
        • Investigational Site Number : 0360001
    • Victoria
      • Melbourne, Victoria, Australien, 3084
        • Investigational Site Number : 0360002
      • Bruges, Belgien, 8000
        • Investigational Site Number : 0560001
      • Brussels, Belgien, 1200
        • Investigational Site Number : 0560008
      • Ghent, Belgien, 9000
        • Investigational Site Number : 0560006
      • Kortrijk, Belgien, 8500
        • Investigational Site Number : 0560007
      • Melsbroek, Belgien, 1820
        • Investigational Site Number : 0560003
      • Overpelt, Belgien, 3900
        • Investigational Site Number : 0560005
      • São Paulo, Brasilien, 01228-000
        • CPHosp Medicina, Ensino e Pesquisa (CPQuali)- Site Number : 0760002
      • São Paulo, Brasilien, 04038-002
        • PSEG Centro de Pesquisa Clínica- Site Number : 0760021
      • São Paulo, Brasilien, 04515-000
        • Jordy Sinapse- Site Number : 0760004
      • São Paulo, Brasilien, 05651-901
        • Hospital Israelita Albert Einstein- Site Number : 0760026
    • Espírito Santo
      • Vitória, Espírito Santo, Brasilien, 29055-450
        • Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760029
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 41820-020
        • Centro de Pesquisas da Clínica IBIS- Site Number : 0760030
    • Federal District
      • Brasília, Federal District, Brasilien, 70200-730
        • L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760003
    • Goiás
      • Goiânia, Goiás, Brasilien, 74605-020
        • Universidade Federal de Goias- Site Number : 0760024
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-320
        • Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760025
    • Paraná
      • Curitiba, Paraná, Brasilien, 81210-310
        • Instituto de Neurologia de Curitiba - Ecoville- Site Number : 0760001
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-902
        • Hospital Moinhos de Vento- Site Number : 0760005
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90110-000
        • IMV Pesquisa Neurológica- Site Number : 0760031
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90480-020
        • Instituto Ceos- Site Number : 0760028
    • Santa Catarina
      • Joinville, Santa Catarina, Brasilien, 89202-165
        • Clínica Neurológica- Site Number : 0760007
    • São Paulo
      • Santo André, São Paulo, Brasilien, 09040-010
        • Prognosis Centro de Pesquisa- Site Number : 0760032
      • Blagoevgrad, Bulgarien, 2700
        • Investigational Site Number : 1000009
      • Panagyurishte, Bulgarien, 4500
        • Investigational Site Number : 1000008
      • Pazardzhik, Bulgarien, 4400
        • Investigational Site Number : 1000007
      • Pleven, Bulgarien, 5800
        • Investigational Site Number : 1000010
      • Pleven, Bulgarien, 5800
        • Investigational Site Number : 1000002
      • Sofia, Bulgarien, 1431
        • Investigational Site Number : 1000001
      • Sofia, Bulgarien, 1407
        • Investigational Site Number : 1000004
      • Sofia, Bulgarien, 1606
        • Investigational Site Number : 1000006
      • Sofia, Bulgarien, 1680
        • Investigational Site Number : 1000005
    • Alberta
      • Calgary, Alberta, Canada, T2N 2T9
        • Investigational Site Number : 1240011
    • British Columbia
      • Burnaby, British Columbia, Canada, V5G 2X6
        • Investigational Site Number : 1240005
      • Vancouver, British Columbia, Canada, V6T 2B5
        • Investigational Site Number : 1240010
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 2Z3
        • Investigational Site Number : 1240018
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • Investigational Site Number : 1240014
      • Ottawa, Ontario, Canada, K1H 8L6
        • Investigational Site Number : 1240002
      • Toronto, Ontario, Canada, M4N 3M5
        • Investigational Site Number : 1240015
      • Toronto, Ontario, Canada, M5B 1W8
        • Investigational Site Number : 1240012
    • Quebec
      • Gatineau, Quebec, Canada, J8Y 1W2
        • Investigational Site Number : 1240001
      • Lévis, Quebec, Canada, G6W 0M5
        • Investigational Site Number : 1240008
      • Montreal, Quebec, Canada, H2X 3E4
        • Investigational Site Number : 1240009
      • Québec, Quebec, Canada, G1J 1Z4
        • Investigational Site Number : 1240003
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Investigational Site Number : 1240006
    • Reg Metropolitana de Santiago
      • Santiago, Reg Metropolitana de Santiago, Chile, 8380456
        • Investigational Site Number : 1520001
      • Santiago, Reg Metropolitana de Santiago, Chile, 8320325
        • Investigational Site Number : 1520002
      • Liverpool, Det Forenede Kongerige, L97LJ
        • Investigational Site Number : 8260009
    • Blaenau Gwent
      • Gwent, Blaenau Gwent, Det Forenede Kongerige, NP20 2UB
        • Investigational Site Number : 8260011
    • Cardiff [Caerdydd Gb-crd]
      • Cardiff, Cardiff [Caerdydd Gb-crd], Det Forenede Kongerige, CF14 4XW
        • Investigational Site Number : 8260007
    • Devon
      • Exeter, Devon, Det Forenede Kongerige, EX2 5DW
        • Investigational Site Number : 8260001
    • England
      • London, England, Det Forenede Kongerige, E11 1NR
        • Investigational Site Number : 8260013
      • Newcastle upon Tyne, England, Det Forenede Kongerige, NE2 4HH
        • Investigational Site Number : 8260006
    • Highland
      • Inverness, Highland, Det Forenede Kongerige, IV2 3UJ
        • Investigational Site Number : 8260010
    • Kent
      • Canterbury, Kent, Det Forenede Kongerige, CT1 3NG
        • Investigational Site Number : 8260003
    • Manchester
      • Salford, Manchester, Det Forenede Kongerige, M6 8HD
        • Investigational Site Number : 8260008
    • Oxfordshire
      • Oxford, Oxfordshire, Det Forenede Kongerige, OX3 9DU
        • Investigational Site Number : 8260004
    • Swansea [Abertawe Gb-ata]
      • Swansea, Swansea [Abertawe Gb-ata], Det Forenede Kongerige, SA6 6SG
        • Investigational Site Number : 8260005
    • Alabama
      • Homewood, Alabama, Forenede Stater, 35209
        • Alabama Neurology Associates- Site Number : 8400115
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85253
        • Perseverance Research Center- Site Number : 8400138
      • Scottsdale, Arizona, Forenede Stater, 85258
        • Imaging Endpoints- Site Number : 8400050
    • California
      • Berkeley, California, Forenede Stater, 94705
        • Sutter East Bay Medical Foundation - Berkeley- Site Number : 8400134
      • Irvine, California, Forenede Stater, 92697
        • University of California Irvine - School of Medicine- Site Number : 8400143
      • La Jolla, California, Forenede Stater, 92037
        • University of California San Diego - La Jolla- Site Number : 8400095
      • Los Angeles, California, Forenede Stater, 90027
        • Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400184
      • Newport Beach, California, Forenede Stater, 92663
        • Hoag Memorial Hospital Presbyterian- Site Number : 8400031
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford Neuroscience Health Center- Site Number : 8400120
      • West Hollywood, California, Forenede Stater, 90048
        • Private Practice - Dr. Regina Berkovich- Site Number : 8400005
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado - Anschutz Medical Campus- Site Number : 8400001
      • Fort Collins, Colorado, Forenede Stater, 80528
        • Advanced Neurology of Colorado- Site Number : 8400148
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06510
        • Yale University School of Medicine- Site Number : 8400081
      • Norwich, Connecticut, Forenede Stater, 06360
        • Hartford Healthcare Medical Group- Site Number : 8400069
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • MedStar Georgetown University Hospital- Site Number : 8400044
    • Florida
      • Altamonte Springs, Florida, Forenede Stater, 32714
        • Neurology of Central Florida- Site Number : 8400147
      • Clearwater, Florida, Forenede Stater, 33761
        • MS & Neuromuscular Center of Excellence- Site Number : 8400015
      • Gainesville, Florida, Forenede Stater, 32608
        • Norman Fixel Institute for Neurological Diseases (FIND)- Site Number : 8400054
      • Maitland, Florida, Forenede Stater, 32751
        • Neurology Associates - Maitland- Site Number : 8400010
      • Orlando, Florida, Forenede Stater, 32806
        • Orlando Health Neuroscience Institute - Downtown Pavilion- Site Number : 8400060
      • Tampa, Florida, Forenede Stater, 33609
        • Axiom Clinical Research of Florida- Site Number : 8400049
      • Tampa, Florida, Forenede Stater, 33612
        • University of South Florida- Site Number : 8400013
      • West Palm Beach, Florida, Forenede Stater, 33407
        • Palm Beach Neurology- Site Number : 8400105
    • Georgia
      • Smyrna, Georgia, Forenede Stater, 30080
        • Joi Life Wellness Group LLC- Site Number : 8400192
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rush University Medical Center- Site Number : 8400102
      • Chicago, Illinois, Forenede Stater, 60637
        • University of Chicago Medical Center- Site Number : 8400055
      • Northbrook, Illinois, Forenede Stater, 60062
        • Consultants in Neurology- Site Number : 8400020
    • Indiana
      • Merrillville, Indiana, Forenede Stater, 46410
        • Neuroscience Institute Center- Site Number : 8400053
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242-1009
        • University of Iowa- Site Number : 8400029
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66103
        • University of Kansas Medical Center- Site Number : 8400084
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40503
        • Baptist Health Lexington- Site Number : 8400149
    • Louisiana
      • Alexandria, Louisiana, Forenede Stater, 71301
        • NeuroMedical Clinic of Central Louisiana- Site Number : 8400159
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Ochsner Medical Center - Jefferson Highway- Site Number : 8400027
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • University of Maryland School of Medicine - Baltimore- Site Number : 8400185
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins Hospital- Site Number : 8400080
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02111
        • Tufts Medical Center- Site Number : 8400003
      • Boston, Massachusetts, Forenede Stater, 02131
        • Boston Clinical Trials- Site Number : 8400178
      • Foxborough, Massachusetts, Forenede Stater, 02035
        • Neurology Center of New England- Site Number : 8400164
      • Wellesley, Massachusetts, Forenede Stater, 02481
        • The Elliot Lewis Center- Site Number : 8400033
      • Worcester, Massachusetts, Forenede Stater, 01655
        • UMass Memorial Medical Center - University Campus- Site Number : 8400028
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Henry Ford Hospital- Site Number : 8400091
      • Farmington Hills, Michigan, Forenede Stater, 48334
        • Michigan Institute for Neurological Disorders- Site Number : 8400004
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Trinity Health Grand Rapids- Site Number : 8400150
      • Owosso, Michigan, Forenede Stater, 48867
        • Memorial Healthcare Institute for Neuroscience- Site Number : 8400123
      • Rochester Hills, Michigan, Forenede Stater, 48307
        • Rochester Medical Group- Site Number : 8400172
    • Minnesota
      • Golden Valley, Minnesota, Forenede Stater, 55422
        • Minneapolis Clinic of Neurology - Golden Valley- Site Number : 8400077
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • M Health Fairview University of Minnesota Medical Center - East Bank- Site Number : 8400056
      • Plymouth, Minnesota, Forenede Stater, 55446
        • Minnesota Center for Multiple Sclerosis- Site Number : 8400073
    • Missouri
      • Ozark, Missouri, Forenede Stater, 65721
        • Sharlin Health and Neurology- Site Number : 8400016
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University- Site Number : 8400076
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89106
        • Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas- Site Number : 8400045
      • Reno, Nevada, Forenede Stater, 89502
        • Renown Regional Medical Center- Site Number : 8400066
    • New Jersey
      • Teaneck, New Jersey, Forenede Stater, 07666
        • Holy Name Medical Center- Site Number : 8400101
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • The University of New Mexico- Site Number : 8400090
    • New York
      • Amherst, New York, Forenede Stater, 14226
        • Dent Neurologic Institute - Amherst- Site Number : 8400129
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai- Site Number : 8400011
      • New York, New York, Forenede Stater, 10032
        • Columbia University Irving Medical Center- Site Number : 8400088
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28210
        • Piedmont HealthCare - Lake Norman Neurology- Site Number : 8400002
      • Raleigh, North Carolina, Forenede Stater, 27607
        • Raleigh Neurology Associates- Site Number : 8400014
      • Winston-Salem, North Carolina, Forenede Stater, 27103
        • Atrium Health - Wake Forest Baptist - Shepherd- Site Number : 8400040
    • North Dakota
      • Fargo, North Dakota, Forenede Stater, 58103
        • Sanford Brain and Spine Center- Site Number : 8400085
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45212
        • Riverhills Neuroscience- Site Number : 8400007
      • Cincinnati, Ohio, Forenede Stater, 45219
        • University of Cincinnati Medical Center- Site Number : 8400117
      • Columbus, Ohio, Forenede Stater, 43210
        • The Ohio State University- Site Number : 8400009
      • Columbus, Ohio, Forenede Stater, 43235
        • The Boster Center for Multiple Sclerosis- Site Number : 8400006
      • Dayton, Ohio, Forenede Stater, 45408
        • UC Health - Elizabeth Place- Site Number : 8400008
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Oklahoma Medical Research Foundation- Site Number : 8400039
    • Oregon
      • Portland, Oregon, Forenede Stater, 97225
        • Providence St. Vincent's Medical Center- Site Number : 8400052
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State Health Milton South Hershey Medical Center- Site Number : 8400176
    • South Carolina
      • Greer, South Carolina, Forenede Stater, 29650
        • Premier Neurology- Site Number : 8400047
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37215
        • Vanderbilt Multiple Sclerosis Center- Site Number : 8400130
    • Texas
      • Dallas, Texas, Forenede Stater, 75243
        • Neurology Consultants of Dallas - Lyndon B Johnson Freeway- Site Number : 8400152
      • Plano, Texas, Forenede Stater, 75024
        • North Texas Institute of Neurology & Headache - Plano- Site Number : 8400083
      • San Antonio, Texas, Forenede Stater, 78258
        • Neurology Center of San Antonio- Site Number : 8400099
      • Sherman, Texas, Forenede Stater, 75092
        • Texas Institute for Neurological Disorders - Sherman- Site Number : 8400018
    • Vermont
      • Burlington, Vermont, Forenede Stater, 05401
        • University of Vermont Medical Center- Site Number : 8400042
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Inova Schar Cancer Institute - Fairfax - Innovation Park Drive- Site Number : 8400109
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Swedish Medical Center - Seattle- Site Number : 8400078
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Medical College of Wisconsin - Milwaukee Campus- Site Number : 8400038
      • Créteil, Frankrig, 94010
        • Investigational Site Number : 2500005
      • Gonesse, Frankrig, 95500
        • Investigational Site Number : 2500017
      • La Tronche, Frankrig, 38700
        • Investigational Site Number : 2500006
      • Lille, Frankrig, 59037
        • Investigational Site Number : 2500009
      • Nancy, Frankrig, 54035
        • Investigational Site Number : 2500016
      • Nice, Frankrig, 06001
        • Investigational Site Number : 2500002
      • Orsay, Frankrig, 91400
        • Investigational Site Number : 2500018
      • Paris, Frankrig, 75019
        • Investigational Site Number : 2500007
      • Paris, Frankrig, 75651
        • Investigational Site Number : 2500014
      • Rennes, Frankrig, 35033
        • Investigational Site Number : 2500003
      • Saint-Herblain, Frankrig, 44800
        • Investigational Site Number : 2500010
      • Strasbourg, Frankrig, 67200
        • Investigational Site Number : 2500001
      • Athens, Grækenland, 124 62
        • Investigational Site Number : 3000005
      • Athens, Grækenland, 115 25
        • Investigational Site Number : 3000003
      • Ioannina, Grækenland, 455 00
        • Investigational Site Number : 3000004
      • Larissa, Grækenland, 411 10
        • Investigational Site Number : 3000001
      • Thessaloniki, Grækenland, 546 36
        • Investigational Site Number : 3000002
      • Rotterdam, Holland, 3015 CE
        • Investigational Site Number : 5280002
      • Bengaluru, Indien, 560022
        • Investigational Site Number : 3560024
      • Hyderabad, Indien, 500082
        • Investigational Site Number : 3560008
      • New Delhi, Indien, 110029
        • Investigational Site Number : 3560017
      • Shimla, Indien, 171001
        • Investigational Site Number : 3560006
      • Bologna, Italien, 40139
        • Investigational Site Number : 3800009
      • Chieti, Italien, 66100
        • Investigational Site Number : 3800014
      • Foggia, Italien, 71100
        • Investigational Site Number : 3800019
      • Novara, Italien, 28100
        • Investigational Site Number : 3800026
      • Palermo, Italien, 90127
        • Investigational Site Number : 3800017
      • Parma, Italien, 43100
        • Investigational Site Number : 3800029
      • Pavia, Italien, 27100
        • Investigational Site Number : 3800005
      • Perugia, Italien, 06156
        • Investigational Site Number : 3800003
      • Ravenna, Italien, 48121
        • Investigational Site Number : 3800030
    • Catania
      • Augusta, Catania, Italien, 96011
        • Investigational Site Number : 3800034
    • Ferrara
      • Cona, Ferrara, Italien, 44124
        • Investigational Site Number : 3800025
    • Firenze
      • Florence, Firenze, Italien, 50134
        • Investigational Site Number : 3800004
    • Genova
      • Genoa, Genova, Italien, 16132
        • Investigational Site Number : 3800011
    • Milano
      • Milan, Milano, Italien, 20132
        • Investigational Site Number : 3800002
      • Milan, Milano, Italien, 20133
        • Investigational Site Number : 3800016
    • Napoli
      • Naples, Napoli, Italien, 80131
        • Investigational Site Number : 3800010
    • Palermo
      • Cefalù, Palermo, Italien, 90015
        • Investigational Site Number : 3800006
    • Roma
      • Rome, Roma, Italien, 00149
        • Investigational Site Number : 3800001
      • Rome, Roma, Italien, 00161
        • Investigational Site Number : 3800013
      • Rome, Roma, Italien, 00168
        • Investigational Site Number : 3800021
    • Varese
      • Gallarate, Varese, Italien, 21013
        • Investigational Site Number : 3800035
      • Chiba, Japan, 260-8677
        • Investigational Site Number : 3920002
      • Fukuoka, Japan, 812-8582
        • Investigational Site Number : 3920013
      • Joyo-Shi, Japan, 610-0113
        • Investigational Site Number : 3800008
      • Kyoto, Japan, 616-8255
        • Investigational Site Number : 3920001
      • Tokyo, Japan, 145-0065
        • Investigational Site Number : 3920011
      • Tokyo, Japan, 160-8582
        • Investigational Site Number : 3920012
      • Toyama, Japan, 939-2716
        • Investigational Site Number : 2500015
    • Fukushima
      • Kōriyama, Fukushima, Japan, 963-8052
        • Investigational Site Number : 3920003
    • Hokkaido
      • Asahikawa, Hokkaido, Japan, 070-0901
        • Investigational Site Number : 3920014
    • Hyōgo
      • Himeji, Hyōgo, Japan, 670-8560
        • Investigational Site Number : 3920007
    • Kanagawa
      • Sagamihara, Kanagawa, Japan, 252-0315
        • Investigational Site Number : 3920010
    • Saitama
      • Higashi-Matsuyama, Saitama, Japan, 355-0005
        • Investigational Site Number : 3920015
    • Tokyo
      • Kodaira, Tokyo, Japan, 187-8551
        • Investigational Site Number : 3920016
      • Beijing, Kina, 100034
        • Investigational Site Number : 1560005
      • Beijing, Kina, 100005
        • Investigational Site Number : 1560007
      • Beijing, Kina, 100050
        • Investigational Site Number : 1560008
      • Changchun, Kina, 130021
        • Investigational Site Number : 1560003
      • Changsha, Kina, 410008
        • Investigational Site Number : 1560011
      • Chengdu, Kina, 610041
        • Investigational Site Number : 1560004
      • Fuzhou, Kina, 350005
        • Investigational Site Number : 1560045
      • Guangzhou, Kina, 510630
        • Investigational Site Number : 1560002
      • Harbin, Kina, 150001
        • Investigational Site Number : 1561027
      • Jiazhuang, Kina, 050000
        • Investigational Site Number : 1560010
      • Shanghai, Kina, 200040
        • Investigational Site Number : 1560001
      • Taiyuan, Kina, 030001
        • Investigational Site Number : 1560006
      • Tianjin, Kina, 300121
        • Investigational Site Number : 1560012
      • Wuhan, Kina, 430030
        • Investigational Site Number : 1560009
      • Xi'an, Kina, 710038
        • Investigational Site Number : 1560013
      • Zhengzhou, Kina, 450052
        • Investigational Site Number : 1560034
      • Katowice, Polen, 40571
        • Investigational Site Number : 6160011
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-309
        • Investigational Site Number : 6160012
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-796
        • Investigational Site Number : 6160018
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 31-501
        • Investigational Site Number : 6160005
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, Polen, 35-055
        • Investigational Site Number : 6160006
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polen, 15-276
        • Investigational Site Number : 6160007
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-081
        • Investigational Site Number : 6160010
      • Zabrze, Silesian Voivodeship, Polen, 41-800
        • Investigational Site Number : 6160004
      • Braga, Portugal, 4710-243
        • Investigational Site Number : 6200001
      • Lisbon, Portugal, 1649-035
        • Investigational Site Number : 6200006
      • Lisbon, Portugal, 1349-019
        • Investigational Site Number : 6200007
      • Lisbon, Portugal, 1169-050
        • Investigational Site Number : 6200011
      • Matosinhos Municipality, Portugal, 4464-513
        • Investigational Site Number : 6200002
      • Riyadh, Saudi Arabien, 11461
        • Investigational Site Number : 6820001
      • Córdoba, Spanien, 14004
        • Investigational Site Number : 7240004
      • Madrid, Spanien, 28034
        • Investigational Site Number : 7240002
      • Madrid, Spanien, 28006
        • Investigational Site Number : 7240006
      • Madrid, Spanien, 28007
        • Investigational Site Number : 7240023
      • Madrid, Spanien, 28040
        • Investigational Site Number : 7240003
      • Madrid, Spanien, 28040
        • Investigational Site Number : 7240022
      • Málaga, Spanien, 29010
        • Investigational Site Number : 7240005
      • Valencia, Spanien, 46026
        • Investigational Site Number : 7240008
      • Zaragoza, Spanien, 50009
        • Investigational Site Number : 7240025
    • Almería
      • Murcia, Almería, Spanien, 30120
        • Investigational Site Number : 7240018
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Spanien, 08035
        • Investigational Site Number : 7240010
      • Barcelona, Barcelona [Barcelona], Spanien, 08003
        • Investigational Site Number : 7240016
    • Basque Country
      • Barakaldo, Basque Country, Spanien, 48903
        • Investigational Site Number : 7240009
    • Catalunya [Cataluña]
      • L'Hospitalet de Llobregat, Catalunya [Cataluña], Spanien, 08907
        • Investigational Site Number : 7240011
    • Gipuzkoa
      • Donostia / San Sebastian, Gipuzkoa, Spanien, 20014
        • Investigational Site Number : 7240012
    • Girona [Gerona]
      • Girona, Girona [Gerona], Spanien, 17190
        • Investigational Site Number : 7240024
    • Las Palmas
      • Las Palmas de Gran Canaria, Las Palmas, Spanien, 35010
        • Investigational Site Number : 7240013
    • Lleida [Lérida]
      • Lleida, Lleida [Lérida], Spanien, 25198
        • Investigational Site Number : 7240015
    • Madrid
      • Majadahonda, Madrid, Spanien, 28222
        • Investigational Site Number : 7240017
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Investigational Site Number : 7240001
    • Pontevedra [Pontevedra]
      • Pontevedra, Pontevedra [Pontevedra], Spanien, 36312
        • Investigational Site Number : 7240014
    • Sevilla
      • Seville, Sevilla, Spanien, 41009
        • Investigational Site Number : 7240007
      • Gothenburg, Sverige, 413 45
        • Investigational Site Number : 7520001
      • Huddinge, Sverige, 141 57
        • Investigational Site Number : 7520005
      • Malmö, Sverige, 205 02
        • Investigational Site Number : 7520003
      • Stockholm, Sverige, 113 65
        • Investigational Site Number : 7520002
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sydkorea, 10408
        • Investigational Site Number : 4100001
      • Seongnam-si, Gyeonggi-do, Sydkorea, 13620
        • Investigational Site Number : 4100007
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Sydkorea, 03080
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Sydkorea, 03722
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Sydkorea, 06351
        • Investigational Site Number : 4100003
      • Brno, Tjekkiet, 625 00
        • Investigational Site Number : 2030011
      • Brno, Tjekkiet, 656 91
        • Investigational Site Number : 2030005
      • Hradec Králové, Tjekkiet, 500 05
        • Investigational Site Number : 2030002
      • Jihlava, Tjekkiet, 586 01
        • Investigational Site Number : 2030006
      • Ostrava, Tjekkiet, 708 52
        • Investigational Site Number : 2030007
      • Prague, Tjekkiet, 150 06
        • Investigational Site Number : 2030008
      • Teplice, Tjekkiet, 415 01
        • Investigational Site Number : 2030009
      • Zlín, Tjekkiet, 762 75
        • Investigational Site Number : 2030001
      • Ankara, Tyrkiet (Türkiye), 06010
        • Investigational Site Number : 7920018
      • Ankara, Tyrkiet (Türkiye), 06800
        • Investigational Site Number : 7920011
      • Bursa, Tyrkiet (Türkiye), 16059
        • Investigational Site Number : 7920020
      • Bursa, Tyrkiet (Türkiye), 16310
        • Investigational Site Number : 7920013
      • Eskişehir, Tyrkiet (Türkiye), 26480
        • Investigational Site Number : 7920005
      • Istanbul, Tyrkiet (Türkiye), 34098
        • Investigational Site Number : 7920002
      • Istanbul, Tyrkiet (Türkiye), 34785
        • Investigational Site Number : 7920007
      • Istanbul, Tyrkiet (Türkiye), 34668
        • Investigational Site Number : 7920009
      • Istanbul, Tyrkiet (Türkiye), 34010
        • Investigational Site Number : 7920012
      • Istanbul, Tyrkiet (Türkiye), 34200
        • Investigational Site Number : 7920016
      • Izmir, Tyrkiet (Türkiye), 35340
        • Investigational Site Number : 7920019
      • Izmir, Tyrkiet (Türkiye), 35360
        • Investigational Site Number : 7920008
      • Kayseri, Tyrkiet (Türkiye), 38039
        • Investigational Site Number : 7920014
      • Konya, Tyrkiet (Türkiye), 42075
        • Investigational Site Number : 7920015
      • Mersin, Tyrkiet (Türkiye), 33070
        • Investigational Site Number : 7920006
      • Samsun, Tyrkiet (Türkiye), 55139
        • Investigational Site Number : 7920004
      • Sultangazi, Tyrkiet (Türkiye), 34265
        • Investigational Site Number : 7920003
      • Van, Tyrkiet (Türkiye), 65080
        • Investigational Site Number : 7920017
      • İzmit, Tyrkiet (Türkiye), 41001
        • Investigational Site Number : 7920001
      • Bielefeld, Tyskland, 33647
        • Investigational Site Number : 2760009
      • Bochum, Tyskland, 44791
        • Investigational Site Number : 2760010
      • Dresden, Tyskland, 01307
        • Investigational Site Number : 2760012
      • Düsseldorf, Tyskland, 40225
        • Investigational Site Number : 2760002
      • Erbach im Odenwald, Tyskland, 64711
        • Investigational Site Number : 2760013
      • Essen, Tyskland, 45147
        • Investigational Site Number : 2760011
      • Heidelberg, Tyskland, 69117
        • Investigational Site Number : 2760014
      • Jena, Tyskland, 07747
        • Investigational Site Number : 2760007
      • Leipzig, Tyskland, 04103
        • Investigational Site Number : 2760003
      • Marburg, Tyskland, 35043
        • Investigational Site Number : 2760008
      • Münster, Tyskland, 48149
        • Investigational Site Number : 2760006
      • Ulm, Tyskland, 89073
        • Investigational Site Number : 2760001
      • Chernivtsi, Ukraine, 58023
        • Investigational Site Number : 8040001
      • Ivano-Frankivsk, Ukraine, 76019
        • Investigational Site Number : 8040009
      • Krykhivtsi, Ukraine, 76493
        • Investigational Site Number : 8040003
      • Kyiv, Ukraine, 02091
        • Investigational Site Number : 8040006
      • Lutsk, Ukraine, 43005
        • Investigational Site Number : 8040008
      • Lviv, Ukraine, 79010
        • Investigational Site Number : 8040004
      • Lviv, Ukraine, 79029
        • Investigational Site Number : 8040002
      • Vinnytsia, Ukraine, 21050
        • Investigational Site Number : 8040005
      • Budapest, Ungarn, 1033
        • Investigational Site Number : 3480003
      • Budapest, Ungarn, 1138
        • Investigational Site Number : 3480004
      • Budapest, Ungarn, 1145
        • Investigational Site Number : 3480006
      • Győr, Ungarn, 9024
        • Investigational Site Number : 3480002

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 60 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant must have a previous diagnosis of RRMS in accordance with the 2017 revised McDonald criteria.
  • Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013 endorsed by an Adjudication Committee.
  • Participant must have documented evidence of disability progression observed during the 12 months before screening. Eligibility will be analyzed by an Adjudication Committee.
  • Absence of clinical relapses for at least 24 months.
  • The participant must have an EDSS score at screening from 3.0 to 6.5 points, inclusive.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • For patients eligible to be treated with siponimod: 1) does not tolerate it due to side effects or safety reasons, or 2) has failed siponimod treatment due to perceived lack of efficacy, or 3) has declined siponimod treatment.

Exclusion Criteria:

  • The participant has a history of infection or may be at risk for infection.
  • The presence of psychiatric disturbance or substance abuse.
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment.
  • Current hypogammaglobulinemia defined by immunoglobulin levels (IgG and/or IgM) below the lower limits of normal (LLN) at Screening or a history of primary hypogammaglobulinemia. Patients with a history of secondary hypogammaglobulinemia induced by anti-C20 monoclonal antibodies (eg, ocrelizumab, ofatumumab, ublituximab, rituximab) may be considered for study inclusion provided their immunoglobulin levels are within the normal limits (WNL) at time of Screening.
  • A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis.
  • The participant has sensitivity to any of the study interventions, or components thereof, or has a drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
  • The participant was previously exposed to frexalimab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Matching placebo

IV, as per respective label

Solution for IV infusion

Eksperimentel: Frexalimab

Frexalimab IV administration

SAR441344 Solution for IV infusion

IV, as per respective label

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period
Tidsramme: Up to 36 months

Defined as Increase from the baseline expanded disability status scale (EDSS) score of ≥1.0 point when the baseline is <5.5, or ≥0.5 point when the baseline is ≥5.5, OR Increase of ≥20% from the baseline time in the 9 hole peg test (9HPT),OR Increase of ≥20% from the baseline time in the timed 25 foot walk (T25FW) test

Up to 36 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Tid til begyndelse af sammensat CCDP bekræftede over 3 måneder i den dobbeltblinde behandlingsperiode
Tidsramme: Op til 36 måneder
Op til 36 måneder
Procentændring i tab af hjernevolumen som detekteret af MR-scanninger i slutningen af ​​dobbeltblind behandlingsperiode sammenlignet med måned 6
Tidsramme: Op til 36 måneder
Op til 36 måneder
Ændring i kognitiv funktion i slutningen af ​​dobbeltblind behandlingsperiode sammenlignet med baseline som vurderet ved symbolcifrede modalitetstest (SDMT)
Tidsramme: Baseline, op til 36 måneder
Baseline, op til 36 måneder
Ændring fra baseline i multipel sklerose Impact Scale 29 version 2 (MSIS-29V2) Spørgeskema score over tid i den dobbeltblinde behandlingsperiode
Tidsramme: Baseline, op til 36 måneder
Baseline, op til 36 måneder
Ændring fra baseline i patientens rapporterede resultatmålinginformationssystem (promis) træthed multipel sklerose (MS) -8a over tid i den dobbeltblinde behandlingsperiode
Tidsramme: Baseline, op til 36 måneder
Baseline, op til 36 måneder
Årlig tilbagefaldsfrekvens i den dobbeltblinde behandlingsperiode vurderet ved protokol definerede bedømmede tilbagefald
Tidsramme: Op til 36 måneder
Op til 36 måneder
Antal deltagere med bivirkninger, SAES, AES, der fører til permanent ophør med studieintervention og AE af særlige interesser (enese)
Tidsramme: Op til 36 måneder
Op til 36 måneder
Antal deltagere med antistof over tid
Tidsramme: Op til 36 måneder
Op til 36 måneder
Skift fra baseline i serum IG -niveauer over tid
Tidsramme: Op til 36 måneder
Op til 36 måneder
Ændring fra baseline i plasma neurofilament let kæde (NFL) niveauer over tid i den dobbeltblinde behandlingsperiode
Tidsramme: Op til 36 måneder
Op til 36 måneder
Frexalimab plasmakoncentration over tid i den dobbeltblinde behandlingsperiode
Tidsramme: Op til 36 måneder
Op til 36 måneder
Time to onset of individual components of the composite, confirmed over 3-months or 6 months in the double-blind treatment period
Tidsramme: Up to 36 months

increase from the baseline EDSS score of ≥1.0 point when the baseline is <5.5, or ≥0.5 point when the baseline is ≥5.5

Up to 36 months
Time to onset of confirmed disability improvement (CDI) in the double-blind treatment period
Tidsramme: Up to 36 months

defined as decrease from the baseline EDSS score of ≥1.0 or ≥ 0.5 points when baseline is ≤5.5 or >5.5 points, respectively, confirmed over 6 months.

Up to 36 months
Number of new and/or enlarging T2 hyperintense lesions per year as detected by MRI
Tidsramme: Up to 36 months

defined as the sum of the individual number of new and/or enlarging T2-hyperintense lesions at all scheduled visits starting after baseline up to the end of double-blind treatment period

Up to 36 months
Number of participants with potentially clinically significant abnormalities (PCSAs) in laboratory tests, ECG, and vital signs during the study period
Tidsramme: Up to 36 months

12-lead ECG (electrocardiogram) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.

Up to 36 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. december 2023

Primær færdiggørelse (Anslået)

24. marts 2028

Studieafslutning (Anslået)

24. marts 2028

Datoer for studieregistrering

Først indsendt

9. november 2023

Først indsendt, der opfyldte QC-kriterier

15. november 2023

Først opslået (Faktiske)

21. november 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EFC17504
  • U1111-1280-7114 (Registry Identifier: ICTRP)
  • 2023-504359-29 (Registry Identifier: CTIS)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner